ClinicalTrials.gg

Peripheral Vascular Diseases clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 443 studies for Peripheral Vascular Diseases across more than 10 countries. 44 are recruiting or about to start. 175 of them are mainly about Peripheral Vascular Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 7 narrower conditions too, such as Peripheral Arterial Disease: 2,077 studies, 369 open.

Status

Completed
263
Status unknown
68
Terminated
43
Recruiting
32
Withdrawn
13
Not yet recruiting
10

Phase

Phase 2
64
Phase 3
54
Phase 1
45
Phase 4
40
Early Phase 1
4

Where

United States
187
Germany
64
Belgium
25
United Kingdom
24
Canada
23
China
22

Who develops what

Add Peripheral Vascular Diseases to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AspirinRecent, limitedPhase 4 trial recorded
Evidence
  • NCT05906199 · SK Chemicals Co., Ltd. · Phase 4 · comparator · “Aspirin 100mg” · registered Jun 2023
  • NCT02227368 · AstraZeneca · Phase 2 · comparator · “Comparator” · registered Aug 2014
  • NCT00557921 · Cogentus Pharmaceuticals · Phase 3 · comparator · “Plavix (clopidogrel 75 mg) and aspirin” · registered Nov 2007
Bayer25% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Mar 2027 est.Etribnabdione 25 mg BID · VivaCell Biotechnology España · Phase 2 named, not the main aimNCT06774040 Evaluation of Safety, Tolerability and Preliminary Efficacy of Etrinabdione in Patients With Peripheral Arterial Disease — primary endpoint: Incidence and severity of Treatment Emergent Adverse Events (TEAEs) · 30 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Peripheral Vascular Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here P2Y12 inhibitors 1 open · Statins 7

Coming up

16studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 32 Peripheral Vascular Diseases studies recruiting now, 19 (59%) set no upper age limit and 4 (13%) stop at 75 or younger. 2 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (13%) take healthy volunteers.

Recruiting studies that take each age, of 32
AgeWomenMen
102 (6%)2 (6%)
1825 (78%)25 (78%)
3026 (81%)26 (81%)
4024 (75%)24 (75%)
5029 (91%)29 (91%)
6529 (91%)29 (91%)
7529 (91%)29 (91%)
8524 (75%)24 (75%)

Across all 443 studies, recruiting or not: 7% stop at 75 or younger and 2% at 65; 8% take children; <1% are for women only and 1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Peripheral Vascular Diseases studies take

Of 68 interventional studies with no phase under Peripheral Vascular Diseases, half reached primary completion within 29 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase29 mo16–51 · 68 studies—33 mo16–53 · 48 studies
Observational31 mo8–95 · 25 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 443. Browse all 443 → or search them.